HSAQ vs. CERS, NVRO, GUTS, TCMD, OBIO, LUNG, SKIN, INO, ANGO, and RCEL
Should you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include Cerus (CERS), Nevro (NVRO), Fractyl Health (GUTS), Tactile Systems Technology (TCMD), Orchestra BioMed (OBIO), Pulmonx (LUNG), Beauty Health (SKIN), Inovio Pharmaceuticals (INO), AngioDynamics (ANGO), and AVITA Medical (RCEL). These companies are all part of the "surgical & medical instruments" industry.
Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Comparatively, 3.4% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cerus received 568 more outperform votes than Health Sciences Acquisitions Co. 2 when rated by MarketBeat users.
Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Cerus' net margin of -19.27%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Cerus' return on equity.
Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.
In the previous week, Cerus had 1 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 1 mentions for Cerus and 0 mentions for Health Sciences Acquisitions Co. 2. Cerus' average media sentiment score of 1.46 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Cerus is being referred to more favorably in the news media.
Cerus has a consensus price target of $3.83, suggesting a potential upside of 119.05%. Given Cerus' higher possible upside, analysts plainly believe Cerus is more favorable than Health Sciences Acquisitions Co. 2.
Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Cerus.
Summary
Cerus beats Health Sciences Acquisitions Co. 2 on 7 of the 13 factors compared between the two stocks.
Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Sciences Acquisitions Co. 2 Competitors List
Related Companies and Tools
